In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions
Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.
You may also be interested in...
US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay the launch of a gene therapy for hemophilia A.
Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.